Benefits
Stress reduction within 3 days
In the published clinical trial, Vanizem demonstrated significant improvements in self-reported tension scores (measured by Profile of Mood States — POMS) within just 3 days of use. The fast 3-day onset is unusually rapid for botanical stress support — most stress ingredients require 4-8 weeks. Effects measured at low doses (100-150 mg/day) support practical formulation.
Sleep quality enhancement (LSEQ)
Vanizem supplementation at doses over 100 mg improved sleep quality scores (measured by Leeds Sleep Evaluation Questionnaire — LSEQ) after just 2 doses vs placebo (p<0.05). Subjects found it easier to get to sleep, had better sleep quality, and improved morning alertness. Distinguishes Vanizem from sleep aids that improve duration without quality.
Anxiety reduction below clinical threshold
In the pilot trial, all participants consuming a dosage of at least 100 mg Vanizem significantly reduced their Hamilton Anxiety Scale (HAM-A) scores below the threshold for anxiety by the end of the study. The 30 participants were otherwise healthy adults experiencing day-to-day stress and anxious feelings. Effect size is clinically meaningful — moving subjects out of the 'anxiety' category.
Mood improvement and vigor
Vanizem improved self-reported sleep quality, mood, vigor, ease of falling asleep, and easier morning awakening in clinical testing. The broad effects span stress, mood, sleep, and morning energy — addressing the connected cluster of issues that many adults face. Mood and vigor effects support daytime quality of life beyond just stress reduction.
Endocannabinoid system mechanism (first in class)
Nektium's in vitro research demonstrated for the first time that Aframomum melegueta targets the endocannabinoid system (eCBs) — a key regulator of stress and emotional responses. Vanizem showed 92% FAAH enzyme inhibition and 85.5% CB2 receptor binding inhibition at tested concentrations. The novel mechanism distinguishes Vanizem from traditional GABAergic or serotonergic stress ingredients.
Multi-system CNS modulation
Beyond the endocannabinoid system, Vanizem affects serotonergic and GABAergic systems — both involved in stress, mood, and sleep regulation. The multi-system modulation provides broader effects than single-target interventions. Mechanism diversity also explains the rapid onset (different pathways respond at different timescales).
Food-status culinary precedent
Aframomum melegueta is considered food in both USA (ODI) and Europe — Grains of Paradise is commonly used in West and North African cuisines. Growing popularity in North America via celebrity chefs. The food-status precedent supports general safety profile and broad formulation applications including functional foods, beverages, and supplements.
Mechanism of action
FAAH enzyme inhibition (endocannabinoid)
Vanizem inhibits Fatty Acid Amide Hydrolase (FAAH) at 92% in vitro. FAAH degrades anandamide — the body's main endogenous cannabinoid that supports mood, stress regulation, and sleep. Inhibiting FAAH preserves anandamide signaling — similar mechanism class as some experimental psychiatric medications. Under stress, the body increases FAAH production; Vanizem helps counter this.
CB2 receptor modulation
Vanizem shows 85.5% CB2 receptor binding inhibition activity. CB2 receptors are part of the endocannabinoid system and are involved in stress, immune response, and inflammation. CB2 modulation supports the broader stress and mood effects without psychoactive effects (CB1 receptors handle psychoactive cannabinoid effects).
Serotonergic system effects
Vanizem affects serotonergic targets — relevant for mood, sleep, and stress regulation. The serotonergic effect complements the endocannabinoid mechanism. Multi-system action explains the broad clinical effects across stress (POMS), anxiety (HAM-A), sleep (LSEQ), and morning alertness — different neurotransmitter systems regulate different aspects of these outcomes.
GABAergic system effects
Vanizem also affects GABAergic targets — GABA is the primary inhibitory neurotransmitter responsible for relaxation, anti-anxiety effects, and sleep induction. GABAergic activity supports the sleep quality improvements and ease-of-falling-asleep effects documented in the clinical trial. Similar mechanism class as benzodiazepines but much milder.
Vanilloid compound bioactivity
The 6-shogaol, 6-paradol, and 6-gingerol vanilloids in Vanizem are structurally similar to capsaicin (the active in chili peppers). Vanilloid compounds can interact with TRPV1 receptors and have documented neuroactive properties. The vanilloid structure may explain part of the rapid onset — vanilloid receptors trigger fast neurological responses.
Clinical trials
Randomized, double-blind, placebo-controlled crossover pilot clinical trial evaluating Vanizem for anxiety, stress, mood, and sleep in middle-aged adults with moderate anxiety. Multi-dose design (50, 100, 150 mg) to establish effective dose. Published in Pharmaceuticals 2025;18:278 (Pérez-Machín et al.).
30 healthy men and women aged 40-50 with day-to-day stress and anxious feelings (44% women).
After 48h intake, Vanizem significantly reduced anxiety and tension related to stress, improved overall mood, and enhanced sleep quality at doses 50-150 mg with no reported side effects. All participants on doses ≥100 mg reduced HAM-A scores below the anxiety threshold by study end. POMS tension scores improved at 3 days. LSEQ sleep quality improved after just 2 doses (p<0.05) at >100 mg. Effects established Vanizem as fast-acting at low doses.
In vitro pharmacological assays evaluating Vanizem's binding and inhibitory activity on endocannabinoid system targets, including CB2 receptor and FAAH enzyme. Foundation for the novel endocannabinoid mechanism positioning. First demonstration that Aframomum melegueta acts on the endocannabinoid system.
Not applicable — in vitro binding and inhibition assays on cellular and enzymatic targets.
Vanizem screened at 200.3 µg/mL exhibited 92% significant FAAH inhibition and 85.5% CB2 receptor binding inhibition. Established the endocannabinoid mechanism for the first time. Also showed effects on serotonergic and GABAergic targets — supporting multi-system CNS modulation. Mechanistic foundation distinguishes Vanizem from generic Grains of Paradise extracts.
Preclinical animal studies on Aframomum melegueta seed extract for antidepressant-like activity. Mouse models including forced swim test, unpredictable chronic mild stress (UCMS) paradigm, sucrose preference test, tail suspension test. Provides class evidence for the central nervous system effects.
Not applicable — preclinical mouse studies of antidepressant-like activity.
Aframomum melegueta extract (25-50 mg/kg) significantly decreased duration of immobility in forced swim test and prevented UCMS-induced anhedonia and anxiety-like behaviors. Suggests antidepressant-like activity. Effects on brain biomarkers (malondialdehyde, glutathione) and hippocampus neuron preservation. Preclinical foundation supporting the human clinical effects.